Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
948 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05569187 | Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer | completed | — | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02601378 | A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. | terminated | Phase 1 | 107 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 29, 2022 | clinicaltrials |
| NCT05541328 | Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel | completed | — | 169 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 15, 2022 | clinicaltrials |
| NCT03064854 | PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | terminated | Phase 1 | 111 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 15, 2022 | clinicaltrials |
| NCT03630159 | Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients(PORTIA) | completed | Phase 1 | 12 | Novartis PharmaceuticalsINDUSTRY | 3 | Aug 15, 2022 | clinicaltrials |
| NCT04559555 | MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 9, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT02734615 | Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | terminated | Phase 1 | 199 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 1, 2022 | clinicaltrials |
| NCT02546674 | Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.(NILOdeepR) | completed | Phase 4 | 171 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 22, 2022 | clinicaltrials |
| NCT05366257 | Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL) | completed | — | 160,602 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 5, 2022 | clinicaltrials |
| NCT05421104 | Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea. | completed | — | 1,576 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 5, 2022 | clinicaltrials |
| NCT05349201 | CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) | completed | — | 273 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT03172936 | Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | terminated | Phase 1 | 106 | Novartis PharmaceuticalsINDUSTRY | 8 | May 3, 2022 | clinicaltrials |
| NCT02900664 | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) | completed | Phase 1 | 283 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 29, 2022 | clinicaltrials |
| NCT04456023 | Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Mar 2, 2022 | clinicaltrials |
| NCT02323126 | Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | terminated | Phase 2 | 64 | Novartis PharmaceuticalsINDUSTRY | 8 | Feb 28, 2022 | clinicaltrials |
| NCT02460224 | Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 / Phase 2 | 490 | Novartis PharmaceuticalsINDUSTRY | 12 | Feb 10, 2022 | clinicaltrials |
| NCT02605967 | Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 122 | Novartis PharmaceuticalsINDUSTRY | 7 | Feb 10, 2022 | clinicaltrials |
| NCT02299505 | Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 306 | Novartis PharmaceuticalsINDUSTRY | 24 | Feb 9, 2022 | clinicaltrials |
| NCT02705963 | A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors | completed | Phase 1 | 19 | Novartis PharmaceuticalsINDUSTRY | 5 | Feb 9, 2022 | clinicaltrials |
| NCT03111992 | Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma | completed | Phase 1 | 26 | Novartis PharmaceuticalsINDUSTRY | 4 | Feb 9, 2022 | clinicaltrials |
| NCT03696771 | Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 4 | Feb 4, 2022 | clinicaltrials |
| NCT02083354 | Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma | completed | Phase 2 | 77 | Novartis PharmaceuticalsINDUSTRY | 5 | Feb 1, 2022 | clinicaltrials |
| NCT02947165 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 9 | Jan 31, 2022 | clinicaltrials |
| NCT03647488 | Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer | completed | Phase 2 | 18 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 24, 2022 | clinicaltrials |
| NCT05153135 | Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors | completed | — | 4,320 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2021 | clinicaltrials |
| NCT05141240 | A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors | completed | — | 4,650 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 16, 2021 | clinicaltrials |
| NCT05108740 | MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 9, 2021 | clinicaltrials |
| NCT02189174 | Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies | terminated | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 3, 2021 | clinicaltrials |
| NCT01677741 | A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | completed | Phase 1 / Phase 2 | 85 | Novartis PharmaceuticalsINDUSTRY | 10 | Nov 24, 2021 | clinicaltrials |
| NCT01750918 | BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) | completed | Phase 1 / Phase 2 | 166 | Novartis PharmaceuticalsINDUSTRY | 8 | Oct 29, 2021 | clinicaltrials |
| NCT00444535 | Lapatinib and Bevacizumab for Metastatic Breast Cancer | completed | Phase 2 | 52 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 25, 2021 | clinicaltrials |
| NCT02213042 | Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 12 | Oct 13, 2021 | clinicaltrials |
| NCT03176264 | PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer | terminated | Phase 1 | 1 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 12, 2021 | clinicaltrials |
| NCT03078751 | Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer(EarLEE-1) | completed | Phase 2 | 54 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 11, 2021 | clinicaltrials |
| NCT03096847 | Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer | completed | Phase 3 | 502 | Novartis PharmaceuticalsINDUSTRY | 1 | Oct 11, 2021 | clinicaltrials |
| NCT00508274 | Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China | terminated | Phase 3 | 52 | Novartis PharmaceuticalsINDUSTRY | 2 | Sep 21, 2021 | clinicaltrials |
| NCT00553358 | Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study(Neo ALTTO) | completed | Phase 3 | 455 | Novartis PharmaceuticalsINDUSTRY | 24 | Sep 21, 2021 | clinicaltrials |
| NCT03525834 | Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. | completed | Phase 4 | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 9, 2021 | clinicaltrials |
| NCT00425555 | Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma | completed | Phase 2 | 139 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 20, 2021 | clinicaltrials |
| NCT00490776 | Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL) | terminated | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
| NCT00644878 | Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib(MACS0254) | terminated | Phase 2 | 18 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
| NCT02177682 | Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients | terminated | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 11, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01524783 | Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)(RADIANT-4) | completed | Phase 3 | 302 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 5, 2021 | clinicaltrials |
| NCT02992483 | Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma | completed | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 3, 2021 | clinicaltrials |
| NCT00742027 | Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma | completed | Phase 2 | 129 | Novartis PharmaceuticalsINDUSTRY | 13 | Jul 28, 2021 | clinicaltrials |
| NCT00171223 | An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha | completed | Phase 2 | 532 | Novartis PharmaceuticalsINDUSTRY | 6 | Jul 22, 2021 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials